AG99 Glaxosmsc 5.25%

Issued: 31 July 2024, London UK

GlaxoSmithKline Capital plc publication of Interim Management Report 2024

GlaxoSmithKline Capital plc (the "Company") today announced the publication on the GSK Group ("GSK") website, www.gsk.com *, of its Interim Management Report in respect of the period ended 30 June 2024.

In compliance with Listing Rule 9.6.1 of the UK Financial Conduct Authority ("FCA"), a copy of the Company's 2024 Interim Management Report has been submitted to the FCA'S National Storage Mechanism (NSM) submission portal via the Electronic Submission System (ESS).

The Company is applying the exemption available to it under the Disclosure and Transparency Rules 6.3.5(1A) and has made the regulated information available in unedited full text on the NSM, rather than setting out the full text of the regulated information within this announcement.

A copy of the Company's Interim Management Report in respect of the period ended 30 June 2024, which includes a description of the principal risks and uncertainties affecting it, together with a Directors' responsibility statement, can be viewed at https://data.fca.org.uk/#/nsm/nationalstoragemechanism.

V A Whyte
Company Secretary
31 July 2024

* https://www.gsk.com/en-gb/company/codes-standards-and-reports/#gsk-capital-plc-annual-reports

Cautionary statement regarding forward-looking statements
GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described under Item 3.D "Risk factors" in GSK's Annual Report on Form 20-F for 2023, and GSK's Q2 Results for 2024.

Registered in England & Wales:

No. 02258699

Registered Office:

980 Great West Road

Brentford, Middlesex

TW8 9GS